Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services tags : Genetown save search
TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138TTX-MC138 is Effective in Animal Models of Human Metastatic Pancreatic Cancer
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 11.94%
H: 0.0%
C: -19.05%
mc138 pre-clinical animal positive cancer pancreatic therapeutics results
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
Published: 2023-11-13 (Crawled : 15:30) - biospace.com/
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -0.79%
H: 12.06%
C: 9.32%
business therapeutics financial results
TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138Evidence of Drug Accumulation in Metastatic Lesions
Published: 2023-10-24 (Crawled : 00:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 19.2%
H: 41.66%
C: 17.78%
mc138 drug therapeutics results study
TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGAStudy showed a 70% Inhibition of Recurrent Tumor Growth
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 14.24%
H: 7.44%
C: -7.36%
melanoma tumors treatment tumor preclinical immunotherapy therapeutics growth
TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical TrialDesigned to demonstrate delivery of TTX-MC138 to metastatic lesions
Published: 2023-08-23 (Crawled : 16:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 1.42%
C: -1.16%
mc138 ttx-mc138 therapeutics
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Published: 2023-08-08 (Crawled : 13:00) - biospace.com/
ABBV | $161.67 -0.38% -0.19% 3.4M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
IRWD | $7.79 -1.14% -1.09% 2.9M
|
Health Technology
|
| O: -3.96%
H: 0.0%
C: -5.41%
linzess sales year pharmaceuticals ironwood
iSpecimen Reports First Quarter 2023 Results Quarterly Revenue Increased 17% Year-Over-Year
Published: 2023-05-04 (Crawled : 17:00) - biospace.com/
ISPC | $0.211 -7.05% -2.71% 100K
|
Professional, Scientific, and T...
|
| O: -2.87%
H: 2.37%
C: -0.59%
results
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Published: 2023-04-26 (Crawled : 13:00) - biospace.com/
CMPX | $1.58 -2.47% -3.85% 130K
|
Professional, Scientific, and T...
|
| O: -1.14%
H: 4.98%
C: 3.83%
conference nasdaq therapeutics
TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio
Published: 2023-04-26 (Crawled : 13:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: -0.96%
H: 2.1%
C: 2.1%
expansion therapeutics
iSpecimen to Participate in the Aegis Virtual Conference on May 4, 2023
Published: 2023-04-24 (Crawled : 12:20) - biospace.com/
ISPC | $0.211 -7.05% -2.71% 100K
|
Professional, Scientific, and T...
|
| O: 1.72%
H: 6.21%
C: -4.52%
conference
iSpecimen to Report First Quarter 2023 Results on May 4, 2023
Published: 2023-04-20 (Crawled : 12:00) - biospace.com/
ISPC | $0.211 -7.05% -2.71% 100K
|
Professional, Scientific, and T...
|
| O: -0.89%
H: 21.79%
C: 11.99%
report results
GreenLight Biosciences Releases Inaugural Sustainability Report
Published: 2023-04-12 (Crawled : 14:00) - biospace.com/
GRNA | $0.2995 -0.03% -0.07% 0
|
Professional, Scientific, and T...
|
| O: 0.53%
H: 0.0%
C: -5.65%
report
TransCode Therapeutics to present at AACR Annual Meeting 2023
Published: 2023-04-06 (Crawled : 14:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: -5.7%
H: 0.0%
C: -9.76%
meeting therapeutics
TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138
Published: 2023-04-05 (Crawled : 18:00) - biospace.com/
RNAZ | $0.5363 -13.68% -14.59% 3.5M
|
Professional, Scientific, and T...
|
| O: 21.9%
H: 21.59%
C: 7.89%
mc138 award ttx-mc138 health year grant therapeutics
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
Published: 2023-04-04 (Crawled : 18:00) - biospace.com/
TRDA | $12.89 -0.46% -0.15% 110K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.43%
C: -5.07%
therapeutics
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Published: 2023-03-23 (Crawled : 13:00) - biospace.com/
HOWL | $5.49 17.06% 14.34% 250K
|
Professional, Scientific, and T...
|
| O: -1.31%
H: 4.42%
C: -3.98%
business year update therapeutics financial results
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
Published: 2023-02-21 (Crawled : 17:00) - biospace.com/
TCRX | $7.69 -0.77% -1.17% 120K
|
Professional, Scientific, and T...
|
| O: 1.76%
H: 0.0%
C: -4.5%
conference therapeutics presentation therapy
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
TRDA | $12.89 -0.46% -0.15% 110K
|
Professional, Scientific, and T...
|
| O: 1.43%
H: 1.54%
C: -0.32%
therapeutics agreement
iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on January 25, 2023
Published: 2023-01-19 (Crawled : 13:20) - biospace.com/
ISPC | $0.211 -7.05% -2.71% 100K
|
Professional, Scientific, and T...
|
| O: -3.26%
H: 4.38%
C: 1.25%
conference
Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023
Published: 2023-01-09 (Crawled : 14:00) - biospace.com/
GLUE | $6.57 -8.88% -9.41% 120K
|
Professional, Scientific, and T...
|
| O: 1.26%
H: 0.0%
C: -15.38%
rosa therapeutics molecular
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.